SecBot SecBot
PRESS-RELEASE ·Filed Mar 10, 2026

DNTH

Dianthus Therapeutics, Inc.
NEUTRAL
Impact 6/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Monitor for underwriter option exercise within 30 days; assess dilution impact given new shares issued and pre-funded warrants outstanding. Evaluate use of proceeds against pipeline milestones to determine capital efficiency.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$85.84
T+0 close · Mar 10, 2026 · via day close
Latest settled
−1.01%
T+60 · $84.97
Vs SPY
−12.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 11 $85.84entry
  2. T+1 · 8mo ago −6.43%α −4.95% · $80.32
  3. T+5 · 8mo ago −8.13%α −5.94% · $78.86
  4. T+20 · 7mo ago +6.78%α +6.26% · $91.66
  5. T+60 · 6mo ago −1.01%α −12.54% · $84.97
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dianthus Therapeutics priced an upsized public offering of 7,313,582 shares at $81.00 per share and pre-funded warrants for 402,468 additional shares at $80.999, raising approximately $625 million in gross proceeds. The funds will support clinical development, commercial readiness, and general corporate purposes, with a 30-day underwriter option to purchase up to an additional 1,157,407 shares.

Key Financial Metrics

Deal Value
$625.0M

Key Facts

  • Priced public offering of 7,313,582 common shares at $81.00 per share
  • Pre-funded warrants issued for 402,468 shares at $80.999, exercisable immediately at $0.001 per share
  • Total gross proceeds: ~$625 million (before expenses)
  • Underwriters granted 30-day option to purchase up to 1,157,407 additional shares
  • Proceeds to fund clinical and preclinical programs, commercial readiness, and general corporate use
  • Offering expected to close on March 12, 2026, subject to customary conditions

Financial Impact

$625 million in gross proceeds, with potential for ~$93.8 million more if underwriters fully exercise option (1,157,407 shares × $81)

dilutioncashequity

Risk Factors

  • Significant near-term dilution from new shares and pre-funded warrants
  • Proceeds dependent on biotech R&D success, which carries high clinical failure risk
  • No guarantee that capital will lead to commercial or regulatory success

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3253481

Track record

23 reports on DNTH

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
  2. Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
  5. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  6. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  7. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
  8. Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  9. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 10, 2026